Literature DB >> 10092588

Thrombin, a survival factor for cultured myoblasts.

C Chinni1, M R de Niese, D J Tew, A L Jenkins, S P Bottomley, E J Mackie.   

Abstract

Three members of the family of protease-activated receptors (PARs), PARs-1, -3 and -4, have been identified as thrombin receptors. PAR-1 is expressed by primary myoblast cultures, and expression is repressed once myoblasts fuse to form myotubes. The current study was undertaken to investigate the hypothesis that thrombin inhibits myoblast fusion. Primary rodent myoblast cultures were deprived of serum to promote myoblast fusion and then cultured in the presence or absence of thrombin. Thrombin inhibited myoblast fusion, but another notable effect was observed; 50% of control cells were apoptotic within 24 h of serum deprivation, whereas less than 15% of thrombin-treated cells showed signs of apoptosis. Proteolysis was required for the effect of thrombin, but no other serine protease tested mimicked the action of thrombin. Neither a PAR-1- nor a PAR-4-activating peptide inhibited apoptosis or fusion, and myoblast cultures were negative for PAR-3 expression. Myoblasts exposed to thrombin for 1 h and then changed to medium without thrombin accumulated apoptosis inhibitory activity in their medium over the subsequent 20 h. Thus the protective action of thrombin appears to be effected through cleavage of an unidentified thrombin receptor, leading to secretion of a downstream apoptosis inhibitory factor. These results demonstrate that thrombin functions as a survival factor for myoblasts and is likely to play an important role in muscle development and repair.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092588     DOI: 10.1074/jbc.274.14.9169

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1.

Authors:  Claire J Chalmers; Kathryn Balmanno; Kathryn Hadfield; Rebecca Ley; Simon J Cook
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

2.  p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling.

Authors:  Douglas J Sheffler; Wesley K Kroeze; Bonnie G Garcia; Ariel Y Deutch; Sandra J Hufeisen; Patrick Leahy; Jens C Brüning; Bryan L Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-10       Impact factor: 11.205

3.  Autologous matrix-induced chondrogenesis is effective for focal chondral defects of the knee.

Authors:  Filippo Migliorini; Nicola Maffulli; Alice Baroncini; Andreas Bell; Frank Hildebrand; Hanno Schenker
Journal:  Sci Rep       Date:  2022-06-04       Impact factor: 4.996

4.  Fibrin glue does not assist migration and proliferation of chondrocytes in collagenic membranes: an in vitro study.

Authors:  Filippo Migliorini; Julia Prinz; Nicola Maffulli; Jörg Eschweiler; Christian Weber; Sophie Lecoutrier; Frank Hildebrand; Johannes Greven; Hanno Schenker
Journal:  J Orthop Surg Res       Date:  2022-06-11       Impact factor: 2.677

5.  The role of protease-activated receptor-1 in bone healing.

Authors:  Shu Jun Song; Charles N Pagel; Therese M Campbell; Robert N Pike; Eleanor J Mackie
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

6.  Prostaglandin F2alpha promotes muscle cell survival and growth through upregulation of the inhibitor of apoptosis protein BRUCE.

Authors:  K M Jansen; G K Pavlath
Journal:  Cell Death Differ       Date:  2008-06-20       Impact factor: 15.828

Review 7.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

8.  Signaling through the TRAIL receptor DR5/FADD pathway plays a role in the apoptosis associated with skeletal myoblast differentiation.

Authors:  J O'Flaherty; Y Mei; M Freer; C M Weyman
Journal:  Apoptosis       Date:  2006-12       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.